Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H3N2 Influenza Challenge Dose-Ranging Study
NCT04978454Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2021
- Primary completion
- Sep 2022
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of influenza a/texas/71/2017 (h3n2)-Duke University in influenza (3 cohorts), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number and Percentage of Participants With Symptomatic Influenza Virus Infection After Challenge at Day 8, Number and Percentage of Participants With Detected Viral Shedding in Nasopharyngeal Swabs at Day 10 and 3 more. Started Aug 2021; status: completed.
02
Drugs
influenza a/texas/71/2017 (h3n2)-Duke University
03
Conditions
influenza
Beyond the preview
Go deeper on NCT04978454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04978454.